Edgewise Therapeutics, Inc. — Director's Dealing 2021

Mar 30, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Edgewise Therapeutics, Inc. (EWTX)
CIK: 0001710072
Period of Report: 2021-03-30

Reporting Person: Wellington Biomedical Innovation Master Investors (Cayman) I L.P. (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-03-30	Common Stock	C	681812	—	Acquired	681812	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-03-30	Series C Preferred Stock	$	C	681812	Disposed		Common Stock (681812)	Direct

Footnotes

F1: Upon the closing of the Issuer's initial public offering, each share of Series C Preferred Stock automatically converted into one share of the Issuer's Common Stock. The Series C Preferred Stock had no expiration date.